Cannabis Science Conference Returns to Portland, Oregon with Renewed Focus on Analytical, Medical, Cultivation, and Psychedelic Scientific Insights
The 2023 Portland show will include four tracks–analytical science, medical cannabis, cultivation, psychedelics–plus a discussion on medical cannabis for veterans, and more!
Cannabis Science Conference (CSC), the premier cannabis science conference event focusing on analytical science, medical cannabis, cultivation, and psychedelics, announced today the return of their groundbreaking event to Portland, Oregon from April 19-21, 2023, a location which is perfectly positioned as a hotbed of cannabis activity and interest, and the epicenter of the new and emerging psychedelic market.
“Portland, Oregon is a natural fit for our Spring 2023 Cannabis Science Conference, with its established cannabis and medical markets, and openness toward emerging markets such as psychedelics,” said Megan L’Heureux, spokesperson for CSC, and the group editorial director of Cannabis Science and Technology and Cannabis Patient Care magazines. “CSC’s goal is to spread information and empowerment through education, and we are bringing a hard-hitting team of professional experts to share knowledge and have in-depth conversations about how to move these niche industries forward. We look forward to tackling topics like using psychedelics and medical cannabis to help veterans and other patient demographics as well as our core topic areas focused on analytical testing and cultivation. Our agenda will hit every topic our audience has been asking to learn more about.”
The agenda will include four main program tracks, with professional expert chairs including Analytical chair Dr. Julie Kowalski, a technical consultant serving the cannabis and hemp testing markets; Cultivation chair Dr. Zacariah L. Hildenbrand, who sits on the Editorial Advisory Board of Cannabis Science and Technology; Medical chair Cherissa Jackson, who served 23 years of active-duty military service with 10 years as a US Air Force Nurse; and Psychedelics chair Dr. Denise Vidot, an epidemiologist at the University of Miami where she is Founder of the International Cannabis and Psychedelic Research Collaborative.
The show will feature several key sessions, including:
- “Low and Ultra-Low Doses of Cannabinoids: Are We Missing the Sweet Spot?” by Dr. Dustin Sulak, DO, Healer.com
- “MDMA/Psychedelic-Assisted Therapy: The Path to Potential FDA Approval” by Dr. Sue Sisley, MD, President of Scottsdale Research Institute (SRI) and President/Founder of Field to Healed Foundation
- A panel discussion on “Results from the First NIH Funded Population-based Study of Medical Marijuana”
- A panel discussion on “Quality Assurance and Safety in Cannabis, Psilocybin, and Hemp”
- A film screening of the movie Unprescribed, and a conversation on the increasing numbers of veterans are turning to cannabis as a safer alternative to pharmaceuticals by filmmaker Steve Ellmore
For the full show agenda and to register, please visit the CSC website.
Ep 24, Part I: Data Transparency in Cannabis Testing with Yasha Khan
November 21st 2024Evan Friedmann interviews Yasha Khan, co-founder of MCR Labs, about his journey into the cannabis industry and his efforts to promote transparency and integrity in laboratory practices. Yasha discusses the origins of MCR Labs, which began in Massachusetts to meet the needs of the soon-to-be legal medical cannabis market. He explains the challenges faced, including result manipulation by labs and the impact on public health. Yasha's Freedom of Information Act (FOIA) project aimed to gather testing data from 37 states, revealed significant discrepancies in potency and mold results. Despite some states' reluctance to share data, Yasha has made much of this data public, leading to collaborative research and publications on various aspects of cannabis testing.
Assessing Cannabis as a Harm Reduction Strategy: Insights from a Large-Scale Study
November 19th 2024A New Zealand study aimed to assess cannabis use as a harm reduction tool. Findings highlight lifestyle factors, and suggest cannabis-focused harm reduction strategies in reducing other substance use such as alcohol.
Ep 23, Part III: Accreditation in the Cannabis Industry with Susan Audino
October 24th 2024In Part III of this episode, host Evan Friedmann is joined by Susan Audino, PhD, founder of S.A. Audino & Associates, LLC, and co-founder of Saturn Scientific, LLC, to examine the complexities of sampling in the cannabis industry, emphasizing the need for proper sampling plans, and methods.
